Close

India sends first vaccine doses to Africa under WHO’s COVAX programme

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

India will make its first shipment of a locally made Covid-19 shot to the equitable vaccine distribution network COVAX which is backed by the World Health Organisation (WHO), the government said.

“Fulfilling our commitment to help the world with Covid-19 vaccines, supplies of Made-in-India vaccine commence today for Africa under COVAX facility,” Anurag Srivastava, spokesman for the Ministry of External Affairs, said on Twitter.

The World Health Organisation this month paved the way for the Oxford University/AstraZeneca vaccine’s global rollout by approving emergency use of the product produced by the Serum Institute of India (SII), the world’s biggest vaccine maker, and SK Bioscience of South Korea.

SII will also soon start producing the Novavax vaccine mainly for poor and middle-income countries.

India, the world’s biggest maker of vaccines, has shipped over 17 million vaccine doses to more than two dozen countries — including around six million as gifts to partners such as Bangladesh and Nepal.

For its own campaign, New Delhi has so far only ordered 31 million doses.

 

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back